THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method for treating an eye disease associated with inflammation and / or vascular proliferation in a subject including administering to the subject a therapeutically effective amount of a compound of Formula 1



Formula 1

wherein R_1 and R_2, which may be the same or different, are selected from the group consisting of H, NHR_6, NR_6R_7, OR_8, halogen, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, fused C_5 to C_{20} aryl or alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_3 is selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_4 is selected from the group consisting of H, OH, OR_6;

R_5 is selected from the group consisting of H, NHR_6, NR_6R_7, OR_8, halogen, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, fused C_5 to C_{20} aryl or alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

X_1 and X_2, which may be the same or different, are selected from the group consisting of a bond, C, O, N and S;

X_3 is C or N;

T is a single or double bond;

m is the integer 0 or 1;

n is an integer between 0 and 4;

R_6 and R_7, which may be the same or different, are selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_8 is selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

or a pharmaceutically acceptable salt thereof;

with the proviso that the compound is not tranilast.

2. The method of claim 1, wherein the compound is a compound of Formula 2



Formula 2

wherein R_1 and R_2, which may be the same or different, are selected from the group consisting of a C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne and a chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

X_1 and X_2 are the same or different and are selected from the group consisting of a bond, O, N and S;

T is a single or double bond;

R_3 is selected from the group consisting of H, C_3 to C_{10} alkene, C_3 to C_{10} alkyne and a chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_4 is selected from the group consisting of H, OH, OR_6;

R_5 is selected from the group consisting of H, NHR_6, NR_6R_7, OR_8, halogen, C_3 to C_{10} alkene, C_3 to C_{10} alkyne and a chain consisting of a heterocyclic or fused ring, any of which may be optionally substituted;

R_6 and R_7, which may be the same or different, are selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_8 is selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted; and

n is an integer between 0 and 4;

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 or claim 2, wherein the compound is a compound of Formula 3



Formula 3

wherein R_9 or R_{10}, which may be the same or different, are selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_8 terminal or non-terminal alkyne or a cyclopentyl, cyclohexyl, cyclohexylmethyl or cyclopentylmethyl group;

or a pharmaceutically acceptable salt thereof.

4. The method of any one of claims 1 to 3, wherein the compound is a compound of Formula 4 or Formula 5



Formula 4



Formula 5

where p is an integer between 1 and 10; and R is selected from the group consisting of H and C_1 to C_{10} alkyl;

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 or claim 2, wherein the compound is a compound of Formula 6 or Formula 7



Formula 6



Formula 7

wherein G is a cyclopentyl ring, a cyclohexyl ring or a 1,4-disubstituted 1,2,3-triazole ring; and

q is an integer between 0 and 6;

or a pharmaceutically acceptable salt thereof.

6. The method of any one of claims 1 to 5, wherein the compound is selected from the group consisting of:



















































or a pharmaceutically acceptable salt thereof.

7. The method of any one of claims 1 to 4, wherein the tranilast compound has the formula



or a pharmaceutically acceptable salt thereof.

8. A method for treating an eye disease associated with inflammation and / or vascular proliferation in a subject including administering to the subject a therapeutically effective amount of a compound of formula 8



Formula 8

wherein:

T is a single bond, a double bond or a triple bond;

R^1, R^2, R^3, R^4, and R^5 are each independently selected from the group consisting of: H, halogen, OH, NO_2, CN, NH_2, optionally substituted C_1-C_{12} alkyl, optionally substituted C_2-C_{12} alkenyl, optionally substituted C_2-C_{12} alkynyl, optionally substituted C_1-C_{10} heteroalkyl, optionally substituted C_3-C_{12} cycloalkyl, optionally substituted C_3-C_{12} cycloalkenyl, optionally substituted C_2-C_{12} heterocycloalkyl, optionally substituted C_2-C_{12} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, optionally substituted C_1-C_{18} heteroaryl, optionally substituted C_1-C_{12} alkyloxy, optionally substituted C_2-C_{12} alkenyloxy, optionally substituted C_2-C_{12} alkynyloxy, optionally substituted C_1-C_{10} heteroalkyloxy, optionally substituted C_3-C_{12} cycloalkyloxy, optionally substituted C_3-C_{12}

cycloalkenyloxy, optionally substituted C_1-C_{12} heterocycloalkyloxy, optionally substituted C_1-C_{12} heterocycloalkenyloxy, optionally substituted C_6-C_{18} aryloxy, optionally substituted C_1-C_{18} heteroaryloxy, optionally substituted C_1-C_{12} alkylamino, SR^{11}, SO_3H, $SO_2NR^{11}R^{12}$, SO_2R^{11}, $SONR^{11}R^{12}$, SOR^{11}, COR^{11}, COOH, $COOR^{11}$, $CONR^{11}R^{12}$, $NR^{11}COR^{12}$, $NR^{11}COOR^{12}$, $NR^{11}SO_2R^{12}$, $NR^{11}CONR^{12}R^{13}$, $NR^{11}R^{12}$, and acyl; provided that at least one of R^1, R^2, R^3, R^4, and R^5 contains a halogen;

R^6 and R^7 are present when T is a single bond or a double bond but not when T is a triple bond, each R^6 and R^7 being independently selected from the group consisting of: H, NO_2, CN, optionally substituted C_1-C_{12} alkyl, optionally substituted C_2-C_{12} alkenyl, optionally substituted C_2-C_{12} alkynyl, optionally substituted C_1-C_{10} heteroalkyl, optionally substituted C_3-C_{12} cycloalkyl, optionally substituted C_3-C_{12} cycloalkenyl, optionally substituted C_2-C_{12} heterocycloalkyl, optionally substituted C_2-C_{12} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, optionally substituted C_1-C_{18} heteroaryl, optionally substituted C_1-C_{12} alkyloxy, optionally substituted C_2-C_{12} alkenyloxy, optionally substituted C_2-C_{12} alkynyloxy, optionally substituted C_1-C_{10} heteroalkyloxy, optionally substituted C_3-C_{12} cycloalkyloxy, optionally substituted C_3-C_{12} cycloalkenyloxy, optionally substituted C_1-C_{12} heterocycloalkyloxy, optionally substituted C_1-C_{12} heterocycloalkenyloxy, optionally substituted C_6-C_{18} aryloxy, optionally substituted C_1-C_{18} heteroaryloxy, optionally substituted C_1-C_{12} alkylamino, SR^{11}, SO_3H, $SO_2NR^{11}R^{12}$, SO_2R^{11}, $SONR^{11}R^{12}$, SOR^{11}, COR^{11}, COOH, $COOR^{11}$, $CONR^{11}R^{12}$, $NR^{11}COR^{12}$, $NR^{11}COOR^{12}$, $NR^{11}SO_2R^{12}$, $NR^{11}CONR^{12}R^{13}$, $NR^{11}R^{12}$, and acyl;

R^8 is selected from the group consisting of: H, a N-protecting group, optionally substituted C_1-C_{12} alkyl, optionally substituted C_2-C_{12} alkenyl, optionally substituted C_2-C_{12} alkynyl, optionally substituted C_1-C_{10} heteroalkyl, optionally substituted C_3-C_{12} cycloalkyl, optionally substituted C_3-C_{12} cycloalkenyl, optionally substituted C_1-C_{12} heterocycloalkyl, optionally substituted C_1-C_{12} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, and optionally substituted C_1-C_{18} heteroaryl;

R^9 is selected from the group consisting of: $COOR^{11}$, $COS\ R^{11}$, OR^{11}, $NR^{11}R^{12}$, and SR^{11};

R^{10} is selected from the group consisting of: H, halogen, OH, NO_2, CN, NH_2, optionally substituted C_1-C_{12} alkyl, optionally substituted C_2-C_{12} alkenyl, optionally substituted C_2-C_{12} alkynyl, optionally substituted C_1-C_{10} heteroalkyl, optionally substituted C_3-C_{12} cycloalkyl, optionally substituted C_3-C_{12} cycloalkenyl, optionally substituted C_2-C_{12} heterocycloalkyl, optionally substituted C_2-C_{12} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, optionally substituted C_1-C_{18} heteroaryl, optionally substituted C_1-C_{12} alkyloxy, optionally substituted C_2-C_{12} alkenyloxy, optionally substituted C_2-C_{12} alkynyloxy, optionally substituted C_1-C_{10} heteroalkyloxy, optionally substituted C_3-C_{12} cycloalkyloxy, optionally substituted C_3-C_{12} cycloalkenyloxy, optionally substituted C_1-C_{12} heterocycloalkyloxy, optionally substituted C_1-C_{12} heterocycloalkenyloxy, optionally substituted C_6-C_{18} aryloxy, optionally substituted C_1-C_{18} heteroaryloxy, optionally substituted C_1-C_{12} alkylamino, SR^{11}, SO_3H, $SO_2NR^{11}R^{12}$, SO_2R^{11}, $SONR^{11}R^{12}$, SOR^{11}, COR^{11}, COOH, $COOR^{11}$, $CONR^{11}R^{12}$, $NR^{11}COR^{12}$, $NR^{11}COOR^{12}$, $NR^{11}SO_2R^{12}$, $NR^{11}CONR^{12}R^{13}$, $NR^{11}R^{12}$, and acyl;

each R^{11}, R^{12} and R^{13} is independently selected from the group consisting of H, optionally substituted C_1-C_{12} alkyl, optionally substituted C_2-C_{12} alkenyl, optionally substituted C_2-C_{12} alkynyl, optionally substituted C_1-C_{10} heteroalkyl, optionally substituted C_3-C_{12} cycloalkyl, optionally substituted C_3-C_{12} cycloalkenyl, optionally substituted C_1-C_{12} heterocycloalkyl, optionally substituted C_1-C_{12} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, and optionally substituted C_1-C_{18} heteroaryl;

m is an integer selected from the group consisting of 0, 1, 2, 3, and 4;

n is an integer selected from the group consisting of 1, 2, 3, and 4, and 5; and

m + n is an integer selected from the group consisting of 1, 2, 3, 4, and 5;

or a pharmaceutically acceptable salt thereof.

9. The method of claim 8, wherein the compound has the formula 9



Formula 9

or a pharmaceutically acceptable salt thereof.

10. The method of claim 8, wherein the compound has the formula 10



Formula 10

or a pharmaceutically acceptable salt thereof.

11. The method of claim 8, wherein the compound is selected from the group consisting of:

100

















5



















10



or a pharmaceutically acceptable salt thereof.

12. The method of claim 8, wherein the compound has the formula



or a pharmaceutically acceptable salt thereof.

13. The method of any one of claims 1 to 12, wherein the eye disease is selected from the group comprising diabetic retinopathy, corneal edema, anterior and posterior uveitis, pterygium, corneal diseases, dry eye, conjunctivitis, allergy- and laser-induced exudation, non-age related macular degeneration, macular edema, age-related macular degeneration and ocular von Hippel-Lindau disease.

14. The method of claim 13, wherein the corneal disease is caused by infection from a microbe or microorganism.

15. The method of claim 14, wherein the microbe or microorganism is selected from any of the groups comprising bacteria, viruses, fungi, amoeba, and parasites.

16. The method of claim 13, wherein the eye disease is diabetic retinopathy.

17. The method of any one of claims 1 to 16, wherein treating the eye disease includes inhibiting the progression of the eye disease, preventing the eye disease, and/or ameliorating a symptom of the eye disease.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

~~181~~. Use of a compound of formula 1



Formula 1

wherein R_1 and R_2, which may be the same or different, are selected from the group consisting of H, NHR_6, NR_6R_7, OR_8, halogen, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, fused C_5 to C_{20} aryl or alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_3 is selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_4 is selected from the group consisting of H, OH, OR_6;

R_5 is selected from the group consisting of H, NHR_6, NR_6R_7, OR_8, halogen, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, fused C_5 to C_{20} aryl or alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

X_1 and X_2, which may be the same or different, are selected from the group consisting of a bond, C, O, N and S;

X_3 is C or N;

T is a single or double bond;

m is the integer 0 or 1;

n is an integer between 0 and 4;

R_6 and R_7, which may be the same or different, are selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_8 is selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

or a pharmaceutically acceptable salt or solvate thereof;

with the proviso that the compound is not tranilast;

~~as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof~~ in the preparation of a pharmaceutical composition for treating an eye disease associated with inflammation and / or vascular proliferation.

~~192~~. The use of claim ~~181~~, wherein the compound is a compound of formula 2



Formula 2

wherein R_1 and R_2, which may be the same or different, are selected from the group consisting of a C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne and a chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

X_1 and X_2 are the same or different and are selected from the group consisting of a bond, O, N and S;

T is a single or double bond;

R_3 is selected from the group consisting of H, C_3 to C_{10} alkene, C_3 to C_{10} alkyne and a chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_4 is selected from the group consisting of H, OH, OR_6;

R_5 is selected from the group consisting of H, NHR_6, NR_6R_7, OR_8, halogen, C_3 to C_{10} alkene, C_3 to C_{10} alkyne and a chain consisting of a heterocyclic or fused ring, any of which may be optionally substituted;

R_6 and R_7, which may be the same or different, are selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_8 is selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted; and

n is an integer between 0 and 4;

or a pharmaceutically acceptable salt thereof;

with the proviso that the compound is not tranilast~~as defined in claim 2~~.

~~203~~. The use of claim ~~181~~ or claim ~~192~~, wherein the compound is a compound of formula 3



Formula 3

wherein R_9 or R_{10}, which may be the same or different, are selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_8 terminal or non-terminal alkyne or a cyclopentyl, cyclohexyl, cyclohexylmethyl or cyclopentylmethyl group;

or a pharmaceutically acceptable salt thereof;

with the proviso that the compound is not tranilast ~~as defined in claim 3~~.

~~214~~. The use of any one of claims ~~181~~ to ~~203~~, wherein the compound is a compound of formula 4 or formula 5



Formula 4



Formula 5

where p is an integer between 1 and 10; and R is selected from the group consisting of H and C_1 to C_{10} alkyl;

or a pharmaceutically acceptable salt thereof ~~as defined in claim 4~~.

~~225~~. The use of claim ~~181~~ or ~~192~~, wherein the compound is a compound of formula 6 or formula 7



Formula 6



Formula 7

wherein G is a cyclopentyl ring, a cyclohexyl ring or a 1,4-disubstituted 1,2,3-

triazole ring; and

q is an integer between 0 and 6;

or a pharmaceutically acceptable salt thereof ~~as defined in claim 5~~.

~~236~~. The use of claim ~~181~~, wherein the compound is selected from the group consisting of:




































MeO
O
N
H
O
CO2H


MeO
O
O


O
MeO


MeO
O

















or a pharmaceutically acceptable salt thereof ~~the compounds as defined in claim 6~~.

~~24~~7. The use of claim ~~18~~1, wherein the compound has the formula



or a pharmaceutically acceptable salt thereof.

8. The use of claim 1, wherein the compound is selected from the group consisting of:



and



;

or a pharmaceutically acceptable salt thereof.

~~25~~9. Use of a compound of formula 8



Formula 8

wherein:

T is a single bond, a double bond or a triple bond;

R^1, R^2, R^3, R^4, and R^5 are each independently selected from the group consisting of: H, halogen, OH, NO_2, CN, NH_2, optionally substituted C_1-C_{12} alkyl, optionally substituted C_2-C_{12} alkenyl, optionally substituted C_2-C_{12} alkynyl, optionally substituted C_1-C_{10} heteroalkyl, optionally substituted C_3-C_{12} cycloalkyl, optionally substituted C_3-C_{12} cycloalkenyl, optionally substituted C_2-C_{12} heterocycloalkyl, optionally substituted C_2-C_{12} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, optionally substituted C_1-C_{18} heteroaryl, optionally substituted C_1-C_{12} alkyloxy, optionally substituted C_2-C_{12} alkenyloxy, optionally substituted C_2-C_{12} alkynyloxy, optionally substituted C_1-C_{10} heteroalkyloxy, optionally substituted C_3-C_{12} cycloalkyloxy, optionally substituted C_3-C_{12} cycloalkenyloxy, optionally substituted C_1-C_{12} heterocycloalkyloxy, optionally substituted C_1-C_{12} heterocycloalkenyloxy, optionally substituted C_6-C_{18} aryloxy, optionally substituted C_1-C_{18} heteroaryloxy, optionally substituted C_1-C_{12} alkylamino, SR^{11}, SO_3H, $SO_2NR^{11}R^{12}$, SO_2R^{11}, $SONR^{11}R^{12}$, SOR^{11}, COR^{11}, COOH, $COOR^{11}$, $CONR^{11}R^{12}$, $NR^{11}COR^{12}$, $NR^{11}COOR^{12}$, $NR^{11}SO_2R^{12}$, $NR^{11}CONR^{12}R^{13}$, $NR^{11}R^{12}$, and acyl; provided that at least one of R^1, R^2, R^3, R^4, and R^5 contains a halogen;

R^6 and R^7 are present when T is a single bond or a double bond but not when T is a triple bond, each R^6 and R^7 being independently selected from the group consisting of: H, NO_2, CN, optionally substituted C_1-C_{12} alkyl, optionally substituted C_2-C_{12} alkenyl, optionally substituted C_2-C_{12} alkynyl, optionally substituted C_1-C_{10} heteroalkyl, optionally substituted C_3-C_{12} cycloalkyl, optionally substituted C_3-C_{12} cycloalkenyl, optionally substituted C_2-C_{12} heterocycloalkyl, optionally substituted C_2-C_{12} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, optionally substituted C_1-C_{18} heteroaryl, optionally substituted C_1-C_{12} alkyloxy, optionally substituted C_2-C_{12} alkenyloxy, optionally substituted C_2-C_{12} alkynyloxy, optionally substituted C_1-C_{10} heteroalkyloxy, optionally substituted C_3-C_{12} cycloalkyloxy, optionally substituted C_3-C_{12} cycloalkenyloxy, optionally substituted C_1-C_{12} heterocycloalkyloxy, optionally substituted C_1-C_{12}

heterocycloalkenyloxy, optionally substituted C_6-C_{18} aryloxy, optionally substituted C_1-C_{18} heteroaryloxy, optionally substituted C_1-C_{12} alkylamino, SR^{11}, SO_3H, $SO_2NR^{11}R^{12}$, SO_2R^{11}, $SONR^{11}R^{12}$, SOR^{11}, COR^{11}, COOH, $COOR^{11}$, $CONR^{11}R^{12}$, $NR^{11}COR^{12}$, $NR^{11}COOR^{12}$, $NR^{11}SO_2R^{12}$, $NR^{11}CONR^{12}R^{13}$, $NR^{11}R^{12}$, and acyl;

R^8 is selected from the group consisting of: H, a N-protecting group, optionally substituted C_1-C_{12} alkyl, optionally substituted C_2-C_{12} alkenyl, optionally substituted C_2-C_{12} alkynyl, optionally substituted C_1-C_{10} heteroalkyl, optionally substituted C_3-C_{12} cycloalkyl, optionally substituted C_3-C_{12} cycloalkenyl, optionally substituted C_1-C_{12} heterocycloalkyl, optionally substituted C_1-C_{12} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, and optionally substituted C_1-C_{18} heteroaryl;

R^9 is selected from the group consisting of: $COOR^{11}$, $COSR^{11}$, OR^{11}, $NR^{11}R^{12}$, and SR^{11};

R^{10} is selected from the group consisting of: H, halogen, OH, NO_2, CN, NH_2, optionally substituted C_1-C_{12} alkyl, optionally substituted C_2-C_{12} alkenyl, optionally substituted C_2-C_{12} alkynyl, optionally substituted C_1-C_{10} heteroalkyl, optionally substituted C_3-C_{12} cycloalkyl, optionally substituted C_3-C_{12} cycloalkenyl, optionally substituted C_2-C_{12} heterocycloalkyl, optionally substituted C_2-C_{12} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, optionally substituted C_1-C_{18} heteroaryl, optionally substituted C_1-C_{12} alkyloxy, optionally substituted C_2-C_{12} alkenyloxy, optionally substituted C_2-C_{12} alkynyloxy, optionally substituted C_1-C_{10} heteroalkyloxy, optionally substituted C_3-C_{12} cycloalkyloxy, optionally substituted C_3-C_{12} cycloalkenyloxy, optionally substituted C_1-C_{12} heterocycloalkyloxy, optionally substituted C_1-C_{12} heterocycloalkenyloxy, optionally substituted C_6-C_{18} aryloxy, optionally substituted C_1-C_{18} heteroaryloxy, optionally substituted C_1-C_{12} alkylamino, SR^{11}, SO_3H, $SO_2NR^{11}R^{12}$, SO_2R^{11}, $SONR^{11}R^{12}$, SOR^{11}, COR^{11}, COOH, $COOR^{11}$, $NR^{11}COR^{12}$, $NR^{11}COOR^{12}$, $NR^{11}SO_2R^{12}$, $NR^{11}CONR^{12}R^{13}$, $NR^{11}R^{12}$, and acyl; providing that R^{10} cannot be $CONR^{11}R^{12}$;

each R^{11}, R^{12} and R^{13} is independently selected from the group consisting of H, optionally substituted C_1-C_{12} alkyl, optionally substituted C_2-C_{12} alkenyl, optionally substituted C_2-C_{12} alkynyl, optionally substituted C_1-C_{10} heteroalkyl, optionally substituted C_3-C_{12} cycloalkyl, optionally substituted C_3-C_{12} cycloalkenyl, optionally substituted C_1-C_{12} heterocycloalkyl, optionally substituted C_1-C_{12} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, and optionally substituted C_1-C_{18} heteroaryl;

m is an integer selected from the group consisting of 0, 1, 2, 3, and 4;

n is an integer selected from the group consisting of 1, 2, 3, 4, and 5; and

m + n is an integer selected from the group consisting of 1, 2, 3, 4, and 5;

or a pharmaceutically acceptable salt or solvate thereof;

~~as defined in claim 8 or a pharmaceutically acceptable salt or solvate thereof~~ in the preparation of a pharmaceutical composition for treating an eye disease associated with inflammation and / or vascular proliferation.

~~26~~10. The use of claim ~~25~~9, wherein the compound has the formula 9



Formula 9

or a pharmaceutically acceptable salt thereof ~~as defined in claim 9~~.

~~27~~11. The use of claim ~~25~~9, wherein the compound has the formula 10



Formula 10

or a pharmaceutically acceptable salt thereof ~~as defined in claim 10~~.

~~28~~12. The use of claim ~~25~~9, wherein the compound is selected from the group consisting of:





X = Cl, Br





























or a pharmaceutically acceptable salt thereof ~~the compounds as defined in claim 11~~.

~~29~~13. The use of claim ~~25~~9, wherein the compound has the formula



or a pharmaceutically acceptable salt thereof.

14. The use of claim 9, wherein the compound has the formula



or a pharmaceutically acceptable salt thereof.

~~30~~15. The use of any one of claims ~~1~~81 to ~~29~~14, wherein the eye disease is selected from the group comprising diabetic retinopathy, corneal edema, anterior and posterior uveitis, pterygium, corneal diseases, dry eye, conjunctivitis, allergy- and laser-induced exudation, non-age related macular degeneration, macular edema, age-related macular degeneration and ocular von Hippel-Lindau disease; and
with the proviso that the compound is not tranilast.

~~31~~16. The use of claim ~~30~~15, wherein the corneal disease is caused by infection from a microbe or microorganism; and
with the proviso that the compound is not tranilast.

~~32~~17. The use of claim ~~31~~16, wherein the microbe or microorganism is selected from any of the groups comprising bacteria, viruses, fungi, amoeba, and parasites; and
with the proviso that the compound is not tranilast.

~~33~~18. The use of any one of claims ~~1~~81 to ~~30~~15, wherein the eye disease is diabetic retinopathy.

19. The use of any one of claims 1 to 18, wherein the pharmaceutical composition is formulated for administration to a human.

~~34~~20. A kit for treating an eye disease associated with inflammation and / or vascular proliferation including:
at least one compound of formula 1



Formula 1

wherein R_1 and R_2, which may be the same or different, are selected from the group consisting of H, NHR_6, NR_6R_7, OR_8, halogen, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, fused C_5 to C_{20} aryl or alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_3 is selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_4 is selected from the group consisting of H, OH, OR_6;

R_5 is selected from the group consisting of H, NHR_6, NR_6R_7, OR_8, halogen, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, fused C_5 to C_{20} aryl or alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

X_1 and X_2, which may be the same or different, are selected from the group consisting of a bond, C, O, N and S;

X_3 is C or N;

T is a single or double bond;

m is the integer 0 or 1;

n is an integer between 0 and 4;

R_6 and R_7, which may be the same or different, are selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

R_8 is selected from the group consisting of H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_3 to C_{10} cycloalkylmethyl, C_3 to C_{10} alkene, C_3 to C_{10} alkyne, aryl, C_5 to C_{20} alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted;

or a pharmaceutically acceptable salt or solvate thereof;

with the proviso that the compound is not tranilast;~~as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof;~~ and

instructions for administering the compound to a subject in order to treat the eye disease.

~~35~~21. The kit of claim ~~34~~20, wherein the compound has the formula



or a pharmaceutically acceptable salt thereof.

~~36. A kit for treating an eye disease associated with inflammation and / or vascular proliferation including:~~
~~at least one compound of formula 8 as defined in claim 8 or a pharmaceutically acceptable salt or solvate thereof; and~~
~~instructions for administering the compound to a subject in order to treat the eye disease.~~

~~37~~22. ~~The kit of claim 36,~~A kit for treating an eye disease associated with inflammation and / or vascular proliferation including:
~~wherein the~~ a compound ~~has~~having the formula



or a pharmaceutically acceptable salt thereof; and
instructions for administering the compound to a subject in order to treat the eye disease.

~~38. The kit of any one of claims 34 to 37, wherein the eye disease is selected from the group comprising diabetic retinopathy, corneal edema, anterior and posterior uveitis, pterygium, corneal diseases, dry eye, conjunctivitis, allergy- and laser-induced exudation, macular degeneration, macular edema, age-related macular degeneration and ocular von Hippel-Lindau disease.~~

~~39. The kit of claim 38, wherein the corneal disease comprises infection from a microbe or microorganism.~~

~~40. The kit of claim 40, wherein the microbe or microorganism is selected from any of the groups comprising bacteria, viruses, fungi, amoeba, and parasites.~~

~~41~~23. The kit of any one of claims ~~34~~20 to ~~38~~22, wherein the eye disease is diabetic retinopathy.